An inherited genetic change, HSD3B1 gene causes Androgen Deprivation Therapy (ADT) to be less effective for treating metastatic prostate cancer. Physician-researcher Nima Sharifi, M.D. published this finding in the October, 2016 The Lancet Oncology.  While Androgen Deprivation Therapy is effective for many men with advanced stage prostate cancer, prostate tumors eventually become resistant to ADT because the tumors make their own androgens.  “A simple blood … Continue reading HSD3B1 gene makes Androgen Deprivation Therapy (ADT) less effective